Treatment with ozoralizumab has been shown to have beneficial effects in the treatment of RA comparable to those of other TNF inhibitors and has been shown to have acceptable tolerability in Phase II/III clinical trials (25). The gene discussed is TNF; the disease is rheumatoid arthritis.